RE:Bayer deal todayLaserStock29 wrote: Money is BIG in BIOTECH
Bayer 400m UPFRONT to LOXO Nuff said... If we announce LAST OF 5 TREATED.. and we can wind the clock up for 90-180 day.. and get another Ph1b for GBM and be the first to cross the BBB in humans... this is the kind of deal id expect.
Bayer has paid $400 million (€340 million) and committed to more than $1 billion more to buy into Loxo Oncology’s tropomyosin receptor kinase (TRK) inhibitor franchise. The agreement puts Bayer in charge of global commercialization of a drug that chalked up a 75% response rate in a midphase trial.
YOU KNOW WHAT THE KEY IS TO THE WHOLE THING: FDA APPROVAL. The next step is to file for approval of larotrectinib in the U.S., something Loxo is still on track to do around the turn of the year. Beyond that lie the filing for approval in Europe and first commercial sales, milestones that will advance the amount Loxo earns from the deal up toward $1 billion. Van Naarden expects to pull in $250 million this year, with $425 million to follow in 2018.
Roger White has stated one thing in 3 years that's truth
the PPS doesn't matter if .22,.33, .44 lol
Ill state my DD again.. the FDA was very very involved in creating the goalposts and yardsticks.. patient selection criteria and results they want for FDA approval for our PDC.
FDA approval = Commercialization = $$$$
Roger get this puppy on the Fast track and lets GOOOOOOOOOOOOO
If RW wants to start a talk with some big pharmaceutical companies in China instead of just hooking up with the former or potential rapers whose intentions are only force RW to do another round of dirty low PP, I can guarantee RW could get the great deal from China, as China has the largest commercial market for cancer treatment, and all the big pharmaceutical just don't care what FDA, All RW needs to do is just change his mind to seek the cheap PP, and send out clear message to the whole world, seek any opportunity to do all kinds of jv that could benefits all sides instead of just satisfing with the shameless rapers.